Sho Miyamoto, Takara Nishiyama, Akira Ueno, Hyeongki Park, Takayuki Kanno, Naotoshi Nakamura, Seiya Ozono, Kazuyuki Aihara, Kenichiro Takahashi, Yuuki Tsuchihashi, et al. Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America. 2023. 120. 52. e2314808120
Takeshi Arashiro, Yuzo Arima, Jin Kuramochi, Hirokazu Muraoka, Akihiro Sato, Kumi Chubachi, Kunihiro Oba, Atsushi Yanai, Hiroko Arioka, Yuki Uehara, et al. Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan. Vaccine. 2023. 41. 47. 6969-6979
Taiga Miyazaki, Naoki Hosogaya, Yuri Fukushige, Sachiko Takemori, Shinpei Morimoto, Hiroshi Yamamoto, Makoto Hori, Yoshihito Ozawa, Yuki Shiko, Yosuke Inaba, et al. A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19. Microbiology spectrum. 2023. 11. 3. e0431122
Takeshi Arashiro, Yuzo Arima, Jin Kuramochi, Hirokazu Muraoka, Akihiro Sato, Kumi Chubachi, Atsushi Yanai, Hiroko Arioka, Yuki Uehara, Genei Ihara, et al. Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan. Open forum infectious diseases. 2023. 10. 6. ofad240
Takeshi Arashiro, Yuzo Arima, Hirokazu Muraoka, Akihiro Sato, Kunihiro Oba, Yuki Uehara, Hiroko Arioka, Hideki Yanai, Jin Kuramochi, Genei Ihara, et al. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023. 76. 3. e108-e115
